Launches testosterone replacement therapy (TRT), its first controlled-substance Rx: compounded sub-Q injection…
HIMS announced (Business Wire, 21 Oct) the biggest expansion of its testosterone franchise yet: three new testosterone replacement therapies on top of the existing Testosterone Rx+ (enclomiphene, launched on 2 May, which stimulates the body's own production). The three TRT additions supplement testosterone directly:
Read more
(1) a compounded subcutaneous injection (twice weekly); (2) a generic testosterone cypionate intramuscular injection (weekly); (3) the FDA-approved oral Kyzatrex. The company says testosterone is its fastest-growing specialty outside weight loss as of Q2, though it launched only three quarters ago; no revenue or user numbers were disclosed. The diagnostic funnel is an at-home Tasso blood collector (FDA-cleared) plus a HIMS lab panel of 22 biomarkers (total T, free T, lipids, glucose and others), read by a licensed physician. Why it matters: TRT is HIMS's first controlled-substance prescription (WIRED, 21 Oct). Testosterone is a US controlled substance under the Anabolic Steroid Control Act of 1990. It requires an upfront video consultation with a physician and ongoing monitoring, and cannot be sold off a questionnaire the way GLP-1s are. The gating is both a moat (it shuts out small telehealth players that cannot run the consult-and-monitor loop) and a cost (higher consultation expense per customer, a larger compliance surface). This maps directly onto the long thesis: retention through a loop of periodic blood draws and dose adjustments, with accumulating 22-biomarker user health data as the Medicine 3.0 moat. TRT itself requires lifelong blood monitoring, so it is naturally a high-retention subscription. Risks: (1) the compounded injection is not FDA-approved and sits in the same regulatory risk bucket as compounded weight-loss formulations. With an FTC privacy complaint and securities class actions active, regulatory attention will not shrink. (2) The release says only 'not available in all states', with no state count and no pricing. (3) TRT causes infertility and demands rigorous screening, so a single medical adverse event is a brand-level risk. Verification point: Q3 earnings on 9 Nov. Watch whether HIMS discloses a standalone testosterone or hormone subscriber count, and whether the share of multi-product subscriptions rises. Noise excluded: wall-to-wall solicitations from securities class action law firms (all the same case, with a lead plaintiff deadline of 2 Nov, originally filed on 3 Sep), stock-move pieces and 13F holdings changes. SEC EDGAR shows no new company filings; the latest 8-K is still the Chief Accounting Officer change of 7 Oct.
Key evidence
- The Business Wire release of 21 Oct adds three new testosterone replacement therapies: (1) a compounded subcutaneous injection, twice weekly; (2) a generic testosterone cypionate intramuscular injection, weekly; (3) the FDA-approved oral Kyzatrex
- The prior offering was only Testosterone Rx+ (enclomiphene, which stimulates the body's own production), launched on 2 May. It is now upgraded to direct testosterone supplementation
- The company says that, as of Q2, testosterone is its fastest-growing specialty outside weight loss, having launched only three quarters ago (no revenue or user numbers disclosed)
- Diagnostic funnel: an at-home Tasso blood collector (FDA-cleared) plus a HIMS lab panel of 22 biomarkers (total T, free T, lipids, glucose and others), read by a licensed physician
- WIRED, 21 Oct: this is HIMS's first controlled-substance prescription offering
- Testosterone is a US controlled substance under the Anabolic Steroid Control Act of 1990. It requires an upfront video consultation with a physician and ongoing monitoring, and cannot be sold off a questionnaire the way GLP-1s are
Show 4 more
- Moat versus cost: tighter regulatory gating shuts out small telehealth players, but raises consultation expense per customer and widens the compliance surface
- This maps onto the long thesis: a subscription loop of periodic blood draws and dose adjustments, plus accumulating 22-biomarker user health data, is the Medicine 3.0 moat
- TRT biology requires lifelong blood monitoring, which makes it a naturally high-retention subscription category
- SEC EDGAR: no new company filings. The latest 8-K is still the Chief Accounting Officer change of 7 Oct
Catalysts to watch
- 9 Nov: HIMS Q3 earnings. Watch for a standalone testosterone or hormone subscriber disclosure and the share of multi-product subscriptions
- State-by-state rollout detail (how many states are covered is not yet disclosed)
- Pricing disclosure for the three TRT products
Risks
- The compounded subcutaneous injection is not FDA-approved, which puts it in the same regulatory risk bucket as compounded weight-loss formulations
- An active FTC privacy complaint and securities class actions (lead plaintiff deadline 2 Nov) mean regulatory attention is already elevated
- The release says only 'not available in all states', with no state count and no pricing disclosed
- TRT causes infertility and demands rigorous screening, so a single medical adverse event is a brand-level risk
- Higher physician consultation costs per customer push up opex relative to questionnaire-only categories
Sources (3)
- Hims & Hers official release on Business Wire (21 Oct)
- WIRED (21 Oct): reporting on the first controlled-substance Rx launch
- SEC EDGAR filings list (checked 22 Oct)
A brief is a lead for our research, not a verified conclusion or advice.